Track Autolus Therapeutics plc's net tangible assets ($110M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), AUTL shows a net tangible assets of $110M. That compares with $370M in the prior-year period — down 70.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AUTL's net tangible assets is now $110M (was $370M) — a 70.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Autolus Therapeutics plc is outperforming or lagging.
Tracking AUTL's net tangible assets over time shows whether Autolus Therapeutics plc is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $370M in the prior-year period — down 70.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Autolus Therapeutics plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $110M) with ownership activity and broader fundamentals.
Autolus Therapeutics plc's net tangible assets is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.